Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialy… Read more
Akebia Therapeutics Inc (AX9) - Net Assets
Latest net assets as of September 2025: €41.59 Million EUR
Based on the latest financial reports, Akebia Therapeutics Inc (AX9) has net assets worth €41.59 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€364.15 Million) and total liabilities (€322.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €41.59 Million |
| % of Total Assets | 11.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -119.86% |
| 10-Year Change | N/A |
| Growth Volatility | 220.33 |
Akebia Therapeutics Inc - Net Assets Trend (2015–2024)
This chart illustrates how Akebia Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Akebia Therapeutics Inc (2015–2024)
The table below shows the annual net assets of Akebia Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-49.19 Million | -60.82% |
| 2023-12-31 | €-30.58 Million | -427.38% |
| 2022-12-31 | €9.34 Million | -87.78% |
| 2021-12-31 | €76.46 Million | -69.12% |
| 2020-12-31 | €247.62 Million | -37.27% |
| 2019-12-31 | €394.76 Million | -37.92% |
| 2018-12-31 | €635.93 Million | +432.91% |
| 2017-12-31 | €119.33 Million | +75.18% |
| 2016-12-31 | €68.12 Million | -48.00% |
| 2015-12-31 | €131.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akebia Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 151697100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.63 Billion | % |
| Total Equity | €-49.19 Million | 100.00% |
Akebia Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Akebia Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Fasten Co Ltd
SHE:000890
|
$283.59 Million |
|
Medigen Vaccine Biologics
TWO:6547
|
$283.60 Million |
|
Boston Omaha Corp
NYSE:BOC
|
$283.63 Million |
|
Meitav Trade Inv Ltd
TA:MTRD
|
$283.72 Million |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
$283.54 Million |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
$283.52 Million |
|
Great Taipei Gas Corp
TW:9908
|
$283.48 Million |
|
Nova Minerals Limited
NASDAQ:NVA
|
$283.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akebia Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -30,584,000 to -49,185,000, a change of -18,601,000.
- Net loss of 69,410,000 reduced equity.
- Share repurchases of 1,272,000 reduced equity.
- New share issuances of 42,649,000 increased equity.
- Other factors increased equity by 9,432,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-69.41 Million | -141.12% |
| Share Repurchases | €1.27 Million | -2.59% |
| Share Issuances | €42.65 Million | +86.71% |
| Other Changes | €9.43 Million | +19.18% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Akebia Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.51 | €1.30 | x |
| 2018-12-31 | €5.44 | €1.30 | x |
| 2019-12-31 | €3.24 | €1.30 | x |
| 2020-12-31 | €1.67 | €1.30 | x |
| 2021-12-31 | €0.43 | €1.30 | x |
| 2022-12-31 | €0.05 | €1.30 | x |
| 2023-12-31 | €-0.16 | €1.30 | x |
| 2024-12-31 | €-0.23 | €1.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akebia Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -43.33%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-191.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -46.35% | 0.00% | 0.00x | 1.09x | €-73.82 Million |
| 2016 | -199.28% | -8843.45% | 0.01x | 4.41x | €-142.56 Million |
| 2017 | -64.45% | -43.21% | 0.49x | 3.05x | €-88.85 Million |
| 2018 | -22.58% | -69.12% | 0.21x | 1.57x | €-207.18 Million |
| 2019 | -70.84% | -83.48% | 0.43x | 1.95x | €-319.13 Million |
| 2020 | -154.86% | -129.85% | 0.46x | 2.60x | €-408.22 Million |
| 2021 | -369.94% | -132.43% | 0.41x | 6.87x | €-290.49 Million |
| 2022 | -990.82% | -31.63% | 0.83x | 37.66x | €-93.50 Million |
| 2023 | 0.00% | -26.68% | 0.81x | 0.00x | €-48.87 Million |
| 2024 | 0.00% | -43.33% | 0.73x | 0.00x | €-64.49 Million |
Industry Comparison
This section compares Akebia Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,200,873,585
- Average return on equity (ROE) among peers: -100.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akebia Therapeutics Inc (AX9) | €41.59 Million | -46.35% | 7.76x | $283.56 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |